Journal Watch · The Lancet Oncology · 2026

International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits.

These recommendations aim to standardise future MSCC trials and audits to improve data consistency and comparability.

Wong HCY, Choi JI, Marta GN et al.The Lancet Oncology3 min readPharma relevance 75/100

DOI: 10.1016/s1470-2045(25)00602-3PMID: 41643700Study type: cohort / observational clinical study

TL;DR

These recommendations aim to standardise future MSCC trials and audits to improve data consistency and comparability.

Key findings

  • Experts agreed on baseline and follow-up assessments, including pain, motor and sensory function, ambulation, and urinary and anal sphincter function.
  • Standardised functional scales, response criteria, endpoint definitions, and timing of assessments were established.
  • A core set of mandatory and secondary endpoints was defined for different MSCC scenarios, along with minimum reporting standards for surgery and radiotherapy toxicity.
  • These recommendations aim to standardise future MSCC trials and audits to improve data consistency and comparability.

Numbers at a glance (from the abstract)

75%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

From June 25, 2024, to Jan 11, 2025, experts from 20 countries participated in two survey rounds, 74 in round 1 and 71 in round 2. Consensus was defined as over 75% agreement. 49 statements reached consensus, including definitions for clinical, radiological, and impending MSCC using the Bilsky scale.

Full abstract (original)

Background: Malignant spinal cord compression (MSCC) is a serious complication of spinal metastases and primary spinal tumours that can severely affect quality of life and overall survival. Clinical trials have used inconsistent definitions, criteria, and endpoints, limiting comparability. We conducted a Delphi consensus process following a systematic review of prospective MSCC trials from Jan 1, 2003, to Feb 26, 2024.

What they did: From June 25, 2024, to Jan 11, 2025, experts from 20 countries participated in two survey rounds, 74 in round 1 and 71 in round 2. Consensus was defined as over 75% agreement. 49 statements reached consensus, including definitions for clinical, radiological, and impending MSCC using the Bilsky scale.

Results & conclusions: Experts agreed on baseline and follow-up assessments, including pain, motor and sensory function, ambulation, and urinary and anal sphincter function. Standardised functional scales, response criteria, endpoint definitions, and timing of assessments were established. A core set of mandatory and secondary endpoints was defined for different MSCC scenarios, along with minimum reporting standards for surgery and radiotherapy toxicity. These recommendations aim to standardise future MSCC trials and audits to improve data consistency and comparability.

Abstract © the authors / The Lancet Oncology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/s1470-2045(25)00602-3 · PubMed 41643700.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking The Lancet Oncology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this The Lancet Oncology study find?

These recommendations aim to standardise future MSCC trials and audits to improve data consistency and comparability.

What type of study is this?

It is a cohort / observational clinical study, published in The Lancet Oncology in 2026. From June 25, 2024, to Jan 11, 2025, experts from 20 countries participated in two survey rounds, 74 in round 1 and 71 in round 2.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/s1470-2045(25)00602-3. PubMed ID: 41643700. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wong HCY, Choi JI, Marta GN et al.. International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits.. The Lancet Oncology (2026). DOI: 10.1016/s1470-2045(25)00602-3.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/international-multidisciplinary-consensus-group-for-malignant-spinal-cor-006023/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides